We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Cognizant (CTSH) Q3: Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Cognizant (CTSH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.44 per share, reflecting an increase of 3.6% compared to the same period last year. Revenues are forecasted to be $5.65 billion, representing a year-over-year increase of 4.4%.
Over the last 30 days, there has been a downward revision of 1.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Cognizant metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Products and Resources' to come in at $1.42 billion. The estimate points to a change of +3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Health Sciences' should arrive at $1.65 billion. The estimate indicates a change of +3% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Financial services' should come in at $1.69 billion. The estimate indicates a change of +7% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Communications, Media and Technology' at $873.50 million. The estimate points to a change of +2.8% from the year-ago quarter.
Shares of Cognizant have demonstrated returns of +16.5% over the past month compared to the Zacks S&P 500 composite's -0.2% change. With a Zacks Rank #3 (Hold), CTSH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Insights Into Cognizant (CTSH) Q3: Wall Street Projections for Key Metrics
In its upcoming report, Cognizant (CTSH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.44 per share, reflecting an increase of 3.6% compared to the same period last year. Revenues are forecasted to be $5.65 billion, representing a year-over-year increase of 4.4%.
Over the last 30 days, there has been a downward revision of 1.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Cognizant metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Products and Resources' to come in at $1.42 billion. The estimate points to a change of +3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Health Sciences' should arrive at $1.65 billion. The estimate indicates a change of +3% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Financial services' should come in at $1.69 billion. The estimate indicates a change of +7% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Communications, Media and Technology' at $873.50 million. The estimate points to a change of +2.8% from the year-ago quarter.
View all Key Company Metrics for Cognizant here>>>Shares of Cognizant have demonstrated returns of +16.5% over the past month compared to the Zacks S&P 500 composite's -0.2% change. With a Zacks Rank #3 (Hold), CTSH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .